22nd Century Group Inc. (XXII) - תחזית צמיחת רווח נקי למניה לשנה הבאה

22nd Century Group (XXII) is developing a unique low-nicotine tobacco, aiming for a monopoly through FDA patents to drive cash flow growth. Expectations for changes in earnings per share demonstrate sensitivity to macro shifts, where 0.00 represents the latest level value. However, the expansion of global behemoths and regulatory barriers create risks. A stable engineering staff and the hiring of compliance experts support the technological foundation.

This indicator measures the market's average expectation for net profit growth rates, allowing investors to assess the future value of the business through the lens of consensus forecasts. When analyzing the projected one-year forward growth of net earnings per share, it should be noted that for 22nd Century Group (XXII), the potential for profit scaling lies not in the agricultural sector, but in high-margin genetic patent licensing.